Search - tctmd.com

Displaying 481 - 500 of 564

Sort: Relevancy | Date

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

POSEIDON: Sliding Scale Hydration for the Prevention of Contrast-Induced AKI

Presenter: Somjot S. Brar

May 09, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation

Acetylcysteine for the Prevention of Renal Outcomes in Patients with Diabetes Undergoing Coronary and Peripheral Angiography

Presenter: Otavio Berwanger

April 18, 2013

Presentation

Colchicine Treatment for Prevention of In-BMS Restenosis in Diabetics

Presenter: S. Deftereos

April 17, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Presentation

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg W. Stone

March 26, 2013

Presentation

Long-term Clinical Follow-up of Immunosuppressive Therapy with Oral Prednisone for the Prevention of Restenosis After PCI

Presenter: Flavio Ribichini

March 21, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation CTO 2013

Perforation Prevention and Management

Presenter: Jeffrey Moses

February 21, 2013

Presentation TCT 2013

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Presenter: Bryan Yan, Chow Innes, Yat Yin Lam, Vivian Lee, Cheuk Man Yu

January 31, 2013

Presentation

Prevention of Contrast-Induced Nephropathy with Na/K Citrate

Presenter: Ivica Markota

January 30, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

Presentation

Use of Medications for Secondary Prevention After CABG Compared with PCI

Presenter: Mark A. Hlatky

December 11, 2012

Advertisement

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

POSEIDON: Sliding Scale Hydration for the Prevention of Contrast-Induced AKI

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Acetylcysteine for the Prevention of Renal Outcomes in Patients with Diabetes Undergoing Coronary and Peripheral Angiography

Colchicine Treatment for Prevention of In-BMS Restenosis in Diabetics

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Long-term Clinical Follow-up of Immunosuppressive Therapy with Oral Prednisone for the Prevention of Restenosis After PCI

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Perforation Prevention and Management

Cost-effectiveness Of Transcatheter Left Atrial Appendage Occlusion Compared With 5 Alternative Anticoagulation Strategies For Stroke Prevention In Atrial Fibrillation: A Markov...

Prevention of Contrast-Induced Nephropathy with Na/K Citrate

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Use of Medications for Secondary Prevention After CABG Compared with PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content